Glooko has announced a partnership with Sanofi, aiming to increase their support of people with diabetes and healthcare professionals by integrating SoloSmart with the Glooko platform.
SoloSmart is a single-piece add-on connected device for intended use with SoloStar and DoubleStar insulin injector pens that records the insulin dose, date and time of injection. This allows for visualisation of data in the Glooko app, which patients can then share with healthcare professionals for connected care in diabetes management. The insulin tracking data can also be linked to other features in the Glooko app such as food tracking, exercise metrics, weight and blood pressure to create actionable insights for people with diabetes.
Through the partnership, Sanofi aims to increase accessibility of digital solutions to people with diabetes, leveraging Glooko’s global footprint of over 8,000 clinics. The SoloSmart cap is currently undergoing integration into the Glooko platform and will be gradually rolled-out in several countries beginning in late 2023. SoloSmart is not currently approved in the U.S.
“We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies” says Russ Johannesson, CEO, Glooko. “Glooko is the first global diabetes data management platform to launch with SoloSmart, something our team is particularly proud of. This will allow us to further expand our global reach aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”
Click here to read the original news story